Neuromed Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neuromed Pharmaceuticals Ltd.
STOCKWATCH: Name, Platform; Time of death, December 2013
They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.
Zalicus shifts focus to pain after lead project Synavive fails in arthritis
It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive, due to a lack of clinically meaningful benefit for rheumatoid arthritis (RA) patients in a Phase IIb study.
CombinatoRx posts profit in Q4
CombinatoRx has reported a fourth quarter profit of $25.2 million on lower R&D spending and gains from its acquisition of Neuromed Pharmaceuticals. The US firm's shares closed up by 8% to $1.36 yesterday after swinging from a fourth-quarter loss of $15.2 million the year before.
CombinatoRx and Neuromed complete merger
CombinatoRx and privately held Neuromed Pharmaceuticals announced yesterday that they have closed their $28.8 million all-stock merger.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.